NCT03901950View on ClinicalTrials.gov

Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

December 30, 2021

Study Completion Date

June 30, 2022

Conditions
Advanced Solid Tumors
Interventions
DRUG

XNW7201 tablets

A wnt pathway inhibitor

Trial Locations (1)

4101

Integrated Clinical Oncology network Pty Ltd, South Brisbane

Sponsors
All Listed Sponsors
lead

Evopoint Biosciences Inc.

INDUSTRY